Sat.Dec 07, 2024

article thumbnail

Rilzabrutinib Improves Platelet Response, Quality of Life in Immune Thrombocytopenia Compared to Placebo

HCPLive

Notably, participants without platelet responses also experienced improvements in fatigue, which may be due to the monoclonal antibodys anti-inflammatory action.

article thumbnail

Texting to Improve Adherence to CVD Medications; Detecting Maternal Cancers

Med Page Today

Cancer 40
article thumbnail

Hydroxyurea Shows Clinical Benefit in HbSC, Misses the Mark on Safety

HCPLive

While the therapy was generally well-tolerated, the PIVOT trial failed its primary endpoint of dose-limiting toxicities.

52
article thumbnail

A Randomized Trial of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation

NEJM Journal Watch - Cardiology

article thumbnail

FDA News Month in Review: November 2024

HCPLive

This new edition of HCPLives monthly newsletter on recent US Food and Drug Administration (FDA) news features highlighted updates from across therapeutic pipelines.

52
article thumbnail

Etavopivat Well-Tolerated With Some Disease-Modifying Activity in SCD

HCPLive

The therapy uses a novel pyruvate kinase activator mechanism and warrants further investigation in an ongoing phase 3 trial.

52